Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Patients with osteogenesis imperfecta (OI) are prone to bone fracture and skeletal deformity, and treatment options for these patients are severely limited.
In this issue of the Journal of Clinical Investigation, Eric Orwoll and colleagues at Oregon Health and Sciences University evaluated the use of the teriparatide, a recombinant human parathyroid hormone, for patients with OI.
Compared with patients taking placebo, OI patients taking teriparatide exhibited increased bone density; however, this effect was limited to patients with a mild form of disease.
In an accompanying Attending Physician article, Nick Bishop of the University of Sheffield and Jennifer Walsh of the Metabolic Bone Centre caution that despite the apparent improvement observed with teriparatide treatment, the best course of action for OI patients is supportive care to limit damage.
ACCOMPANYING THE ATTENDING PHYSICIAN TITLE: Osteogenesis imperfecta in adults
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Bones / Orthopedics category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Journal of Clinical Investigation. "Clinical evaluation of teriparatide treatment for osteogenesis imperfecta." Medical News Today. MediLexicon, Intl., 29 Jan. 2014. Web.
16 Apr. 2014. <http://www.medicalnewstoday.com/releases/271794>
Journal of Clinical Investigation. (2014, January 29). "Clinical evaluation of teriparatide treatment for osteogenesis imperfecta." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/271794.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.